Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Study sponsor: Iovance Biotherapeutics, Inc. · IOVA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-08-08Actual
Enrollment · participants64Actual
Source updated2023-10-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.